A comparison of intensive individualised behavioural support and traditional medical treatment for the behavioural and psychological symptoms of dementia (BPSD).
Phase 1
- Conditions
- The behavioural and psychological symptoms of dementia (BPSD)Neurological - Dementias
- Registration Number
- ACTRN12607000344493
- Lead Sponsor
- Dr Kuruvilla George, Consultant Psychiatrist and Director, Eastern Health's Aged Persons Mental Health Service
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. Participants will all have dementia, with a score of less than 24 on the Mini Mental State Examination (MMSE). 2.Participants will all present with at least one of the behavioural symptoms itemised on the Cohen-Mansfield Agitation Inventory (CMAI)3. Participants will all have informed consent to participate granted by their next of kin4. Participants will all reside in an aged care residential facility (high or low care)
Exclusion Criteria
1. MMSE score of 24 or above2. No behavioural symptoms itemised on the CMAI3. Informed consent not granted by next of kin4. Participant does not reside in an aged care residential facility
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in the severity and frequency of BPSD and carer stress.[Measured at baseline, 8-10 weeks post baseline and at 6 months follow-up.];Improvement in participant well-being. [Measured at baseline, 8-10 weeks post baseline and at 6 months follow-up.]
- Secondary Outcome Measures
Name Time Method Reduced use of medical services (GP visits, admissions to ED or psychiatric inpatient units).[The number of GP visits and admissions will be recorded for the 2 months prior to each measurement point (baseline, 8-10 weeks post baseline and 6 months follow-up).];Reduced use of psychotropic medication and medication side-effects.[Current psychotropic medications will be listed at each measurement point. Side-effects will be assessed from a file review for the 2 week period prior to each measurement point.]